FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

UK Authorities Tighten Regulations on P2P Crypto Trading

New measures aim to enhance security for crypto traders in the peer-to-peer market.Highlights: UK authorities introduce new regulations...
FinTech

Citi Wealth Strengthens Services with New AI-Powered Team Member

Citi Wealth Management introduces advanced AI technology for enhanced client experience.Highlights: Citi Wealth Management has launched a new...
FinTech

Coinbase Lists First GBP Stablecoin, Expanding Market Options

The new stablecoin aims to enhance trading in the UK market.Highlights: Coinbase has launched the first GBP stablecoin.This...
FinTech

Former Royal Mint Executives Secure Backing for Precious Metals Trading Platform

New platform aims to modernize precious metals trading for investors.Highlights: Former Royal Mint executives launch a new trading...